This site contains promotional information intended only for healthcare professionals resident in the United Kingdom

Visit Pfizer Medical site

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
Linked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
EN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
Linked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
EN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias
Search

Menu

Close

Sign In or RegisterLog Out
Pfizer MedicinesTherapy AreasExplore ContentEventsVideosMaterialsFeatured ArticlesLet’s ConnectSupplyAlliance HealthcareOff-contract claims

Adverse event reporting can be found at the bottom of the page

About Zinforo

About Zinforo

OverviewExtended spectrum coverage
Dosing

Dosing

Adult & adolescent dosingNeonatal & paediatric dosing
Efficacy & Safety

Efficacy & Safety

EfficacyFOCUS Phase III Trial (CAP)CANVAS Phase III Trial (cSSTI)ASIA CAP Phase III TrialPaediatric EfficacyAdult safetyPaediatric Safety
Clinical & Scientific Data

Clinical & Scientific Data

Patient Risk FactorsCAP patient profilescSSTI patient profilesCAPTURE study
Support & Resources

Support & Resources

Videos & case studiesVideos
Materials

Information on how to access prescribing information and adverse event reporting can be found at the bottom of the page.

Zinforo efficacy has been confirmed in cSSTI and CAP patients in a real-world setting

​​​​​​​CAPTURE was a retrospective cohort study relating to current treatment practice in the US. In CAPTURE, 'clinical success' was defined as clinical cure with no further need for antibiotic therapy or clinical improvement with switch to oral agents at end of Zinforo® treatment. As CAPTURE was a retrospective chart review study, it has the limitations inherent to this study design.5,10

CAP: Clinical success in selected subgroups of the CAPTURE study||*2,5cSSTI: Clinical success in selected subgroups of the CAPTURE study2-4Explore MoreDiscover specific information on the use of Zinforo in neonates, infants and children here:

†Zinforo is suitable for patients with a range of BMIs, and doesn't need to be dosed on a weight basis.4
‡Normal/mild renal insufficiency, or moderate or severe renal insufficiency. Overall clinical success rates were 88–91%.9
||CAPTURE was a retrospective cohort study relating to current treatment practice in the US. In CAPTURE, 'clinical success' was defined as clinical cure with no further need for antibiotic therapy or clinical improvement with switch to oral agents at end of Zinforo® treatment. As CAPTURE is a retrospective chart review study, it has the limitations inherent to this study design.5,10​​​​​​ 
*Shown not to be statistically significant10 

Abbreviations

CAP, community-acquired pneumonia; cSSTI, complicated skin and soft tissue infections; CAPTURE, Clinical Assessment Program and TEFLARO Utilization Registry; NS, non significant

Prescribing Information​​​​​​​

Zinforo® (ceftaroline fosamil)

Great Britain
Zinforo 600 mg powder for concentrate for solution for infusion

Northern Ireland
Zinforo 600 mg powder for concentrate for solution for infusion 

References

ZINFORO. Summary of Product CharacteristicsMaggiore C, et al. Expert Rev Clin Pharmacol 2015;8:141–53Santos PD, et al. J Chemother 2013;25:341–6Evans JD, et al. Postgrad Med 2014;126:128–34Udeani G, et al. Hosp Prac 2014;42:109–15Laudano JB. J Antimicrob Chemother 2011;66(Suppl.3):iii11-iii18Garrison MW, et al. Expert Rev Anti Infect Ther 2012;10:1087-103Drusano, GL. J Antimicrob Chemother 2011;66(Suppl3):iii61–7Friedland D, et al. Antimicrob Agents Chemother 2012;56;2231–6Eckburg P, et al. Infect Dis Clin Pract 2012;20:254–60
PP-ZFO-GBR-0233. September 2021
Tolerability profile of Zinforo

Access data on the safety profile of Zinforo as established in key Phase III clinical trials

View tolerability profile Loading
Discover more about the risk factors associated with disease severity, comorbidities and resistance in CAP and cSSTI Patient Risk Factors Loading

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search 

for MHRA Yellow Card in Google Play or Apple App Store

 

Adverse events should also be reported to Pfizer Medical Information on 01304 616161

PfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign In or RegisterAccountSign Out

This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc

 

This website is brought to you by Pfizer Limited, a company registered in England 

and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ

 

Copyright © 2023 Pfizer Limited. All rights reserved.

 

VAT registration number GB201048427

PP-UNP-GBR-7284 November 2023
For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-3863. November 2021

YesNo
You are now leaving PfizerPro​​​​​

​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site.​​​​​​​​​​​​​​

​​​​​​​PP-PFE-GBR-3858. November 2021​​​​​​​
​​​​​​​
You are now leaving PfizerPro
​​​​​​​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​Pfizer medicines or 
business which it has provided or reviewed.

PP-PFE-GBR-3859. November 2021
​​​​​​​